Botulinum toxin type A, BoNT-A

Phase 1Small molecule

IInstituto Mexicano del Seguro Social

Botulinum toxin type A, BoNT-A is one of 59 small molecule programs targeting Spasticity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SpasticityActive, not recruiting

StrokeActive, not recruiting

SpasticityPreclinical

Active, not recruiting

StrokePhase 1

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Folvite

Eli Lilly

Preclinical

1 2

Zometa

Pfizer

Preclinical

1 3

Pradaxa

Boehringer Ingelheim

Preclinical

3 4

Alka-Seltzer

AAbbott

Preclinical

1 5

Haldol

DDePuy Orthopaedics

Preclinical

1 6

Direct Anticoagulant

Bayer

Preclinical

3 7

Carbidopa-Levodopa

Neurocrine Biosciences

Preclinical

1 8

Botulinum Toxin a

GSK

Preclinical

1 9

Inderal

Mylan Pharmaceuticals Inc

Anticoagulants

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Active, not recruiting

Stroke

NCT06811142

Clinical

Trials by Indication[1]

Spasticity1 trial

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

Completed·JJoAnn Harnar·N/A·NCT00945295·31 enrolled

Stroke1 trial

Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence

Active, not recruiting·IInstituto Mexicano del Seguro Social·Phase 1·NCT06811142·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Botulinum toxin type A, BoNT-A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botulinum toxin type A, BoNT-A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botulinum toxin type A, BoNT-A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto Mexicano del Seguro Social company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInstituto Mexicano del Seguro Social

Botulinum toxin type A, BoNT-A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Spasticity1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News